Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Locally Advanced Cervical Cancer
NCT03612791Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Aug 2018
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in Cervical Cancer (CC) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Progression-Free Survival at 24 months. Started Aug 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03612791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03612791.